RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

Clinical trial NCT07735624 · RECRUITING

Trial details

NCT number: NCT07735624
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Early Rectal Cancer Stage I Rectal Cancer Microsatellite Stable Rectal Carcinoma

Start date: 2026-09-01
Primary completion: 2027-01-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.